Unresectable or Metastatic Hepatocellular Carcinoma research hub

Visugromab, Nivolumab and Lenvatinib Compared to Double Placebo and Lenvatinib in Unresectable or Metastatic Hepatocellular Carcinoma Post Anti-PD-(L)1 Failure

This study looks at new treatments for advanced liver cancer that hasn't responded to initial therapy. It combines a new medicine, visugromab, with existing treatments (nivolumab and lenvatinib) to see if this mix is more effective and safe than lenvatinib alone.